Skip to main content

What the FDA labels say about taking them together

Erlotinib and phenytoin

Erlotinib's FDA label of June 10, 2024 names phenytoin in its drug interactions section; the phenytoin labels PlainMeds reads (2) do not name erlotinib. The erlotinib label: “Increase the erlotinib dosage if co-administration with CYP3A4 inducers is unavoidable.”

Check it at the source: the erlotinib FDA label on DailyMed (effective June 10, 2024, Alembic Pharmaceuticals Limited); the phenytoin FDA label on DailyMed (effective October 15, 2024, Mylan Pharmaceuticals Inc.).

What does the erlotinib label say about phenytoin?

Erlotinib label, drug interactions

Increase the erlotinib dosage if co-administration with CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin, rifabutin, rifapentine, phenobarbital and St. John's wort) is unavoidable [see Dosage and Administration (2.4)].

Source: FDA drug label (ERLOTINIB HYDROCHLORIDE), Alembic Pharmaceuticals Limited, effective June 10, 2024 (SPL set ab6f3cb3-34a8-4492-a5d7-fb6b055a2d6b), via openFDA; the full label on DailyMed

What does the phenytoin label say about erlotinib?

Phenytoin's label (effective October 15, 2024) and its 1 other brand-application label do not name erlotinib in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Phenytek), Mylan Pharmaceuticals Inc., effective October 15, 2024 (SPL set 0f94c791-8b07-4b41-927e-c9f28bec5f60), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

10Erlotinib generic labelers
29Phenytoin generic labelers
ErlotinibPhenytoin
Labeled forLung cancerSeizures and epilepsy
Boxed warningNoNo
Pharmacy cost (NADAC)n/a$0.145 per capsule 100 mg capsule
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?